Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

First Posted Date
2014-10-01
Last Posted Date
2014-12-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02254148
Locations
🇩🇪

1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

First Posted Date
2014-09-30
Last Posted Date
2014-09-30
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
22
Registration Number
NCT02252731
Locations
🇩🇪

Parexel International GmbH, Berlin, Germany

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

First Posted Date
2014-09-25
Last Posted Date
2019-03-29
Lead Sponsor
Yangzhou University
Target Recruit Count
124
Registration Number
NCT02247414
Locations
🇨🇳

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China

Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves

First Posted Date
2014-09-16
Last Posted Date
2014-09-16
Lead Sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Target Recruit Count
40
Registration Number
NCT02240927
Locations
🇹🇷

Kosuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey

Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis

First Posted Date
2014-09-16
Last Posted Date
2014-09-16
Lead Sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Target Recruit Count
180
Registration Number
NCT02240953
Locations
🇹🇷

Kosuyolu Kartal Heart Training and Research Hospital, İstanbul, Turkey

Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

First Posted Date
2014-09-12
Last Posted Date
2015-09-23
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Target Recruit Count
60
Registration Number
NCT02238535
Locations
🇷🇺

State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

First Posted Date
2014-09-12
Last Posted Date
2019-01-02
Lead Sponsor
Yangzhou University
Target Recruit Count
60
Registration Number
NCT02238444
Locations
🇨🇳

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02183389
© Copyright 2024. All Rights Reserved by MedPath